Moteur de recherche d’entreprises européennes
Financement de l’UE (4 023 617 €) : Une approche nanovaccinale pour le traitement du cancer du pancréas Hor17/09/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Une approche nanovaccinale pour le traitement du cancer du pancréas
A Nanovaccine Approach For The Treatment of Pancreatic Cancer By Multicomponent Immuno-Modulation: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in men and women and still fatal in over 90% of patients. It is characterised by its extremely aggressive nature where it is also responsible for the highest mortality rate compared to other major cancers, resulting in excess of 250,000 deaths worldwide per annum. Current state-of-art therapies for advanced PDAC including chemo- and/or radiotherapy, despite extensive efforts, have met with only limited success. Surgery is only applicable for those with early stages of the disease, or to relieve symptoms, if the cancer is blocking the bile duct or the bowel. There are two major reasons for the resistance of PDAC to conventional therapy. Firstly, PDAC has a very defining hallmark, where an abundance of stromal content is present in the tumour microenvironment (TME) to form a physical and biochemical barrier. Secondly, during progression of the disease, the body's immune system is hijacked to support the proliferation of the cancer. New approaches, such as immunotherapy, are therefore needed where it has already shown promise in overcoming many aspects of this resistance. Immunotherapy has the potential to treat minimal residual disease after pancreatic resection (surgery) as well as for metastatic and non-resectable PDAC. Our objective for this project is to bring together a multidisciplinary and intersectoral group to develop novel vaccine approaches, including use of multiple immunomodulating components.
| ACADEMISCH ZIEKENHUIS LEIDEN | 531 240 € |
| Danmarks Tekniske Universitet | 0,00 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 265 620 € |
| GOOD BIOMARKER SCIENCES B.V. | 265 620 € |
| Institut National de la Sante et de la Recherche Medicale | 274 802 € |
| KLINIKUM DER UNIVERSITAET REGENSBURG | 0,00 € |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | 505 577 € |
| PERCUROS B.V. | 265 620 € |
| Polypure AS | 292 342 € |
| Statens Serum Institut | 297 522 € |
| STIFTUNG LEIBNIZ-INSTITUT FUR IMMUNTHERAPIE | 252 788 € |
| TECHNISCHE UNIVERSITAET MUENCHEN | 252 788 € |
| TECHNISCHE UNIVERSITEIT DELFT | 265 620 € |
| The University of Birmingham | 303 173 € |
| Universitat de Barcelona | 250 905 € |
https://cordis.europa.eu/project/id/861190
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.